Together, our data indicate that combining IL-7–CBD + CBD–IL-12 dual therapy with αPD-1 can overcome CPI resistance and deliver remarkable therapeutic outcomes in very challenging and clinically relevant cancer models. Here, IL7 is linked to cancer.